Market Closed -
Hong Kong S.E.
04:08:28 2024-05-24 am EDT
|
5-day change
|
1st Jan Change
|
3.34
HKD
|
0.00%
|
|
-10.70%
|
-8.49%
|
Fiscal Period: December |
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
5,209
|
1,990
|
2,149
|
2,007
|
-
|
-
|
Enterprise Value (EV)
1 |
2,718
|
-223.7
|
177.8
|
78.26
|
621.1
|
1,304
|
P/E ratio
|
-0.96
x
|
-3.54
x
|
-4.95
x
|
-3.78
x
|
-3.3
x
|
-3.19
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
230
x
|
-
|
113
x
|
11.9
x
|
7.88
x
|
6.45
x
|
EV / Revenue
|
120
x
|
-
|
9.33
x
|
0.47
x
|
2.44
x
|
4.19
x
|
EV / EBITDA
|
-8.6
x
|
0.46
x
|
-0.36
x
|
-1.63
x
|
-1.02
x
|
-1.89
x
|
EV / FCF
|
-15.2
x
|
0.62
x
|
-0.39
x
|
-0.44
x
|
-51.8
x
|
-4.04
x
|
FCF Yield
|
-6.58%
|
162%
|
-256%
|
-225%
|
-1.93%
|
-24.8%
|
Price to Book
|
2.05
x
|
0.75
x
|
1.08
x
|
1.12
x
|
1.76
x
|
3.37
x
|
Nbr of stocks (in thousands)
|
702,578
|
701,774
|
647,858
|
647,794
|
-
|
-
|
Reference price
2 |
7.415
|
2.835
|
3.318
|
3.097
|
3.097
|
3.097
|
Announcement Date
|
3/18/22
|
3/15/23
|
3/12/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
22.68
|
-
|
19.06
|
168
|
254.7
|
311.2
|
EBITDA
1 |
-316.2
|
-481.4
|
-492.7
|
-48.14
|
-608.6
|
-689.5
|
EBIT
1 |
-328.2
|
-497.2
|
-511.1
|
-54.67
|
-227.3
|
-543.2
|
Operating Margin
|
-1,447.05%
|
-
|
-2,681.41%
|
-32.54%
|
-89.21%
|
-174.57%
|
Earnings before Tax (EBT)
1 |
-1,810
|
-495.6
|
-431.6
|
-50
|
-
|
-
|
Net income
1 |
-1,810
|
-495.6
|
-431.6
|
-517.5
|
-785.3
|
-794.7
|
Net margin
|
-7,979.87%
|
-
|
-2,264.34%
|
-308.02%
|
-308.28%
|
-255.35%
|
EPS
2 |
-7.710
|
-0.8000
|
-0.6700
|
-0.8200
|
-0.9400
|
-0.9700
|
Free Cash Flow
1 |
-178.8
|
-363.5
|
-454.3
|
-176
|
-12
|
-323
|
FCF margin
|
-788.09%
|
-
|
-2,383.68%
|
-104.76%
|
-4.71%
|
-103.79%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/18/22
|
3/15/23
|
3/12/24
|
-
|
-
|
-
|
Fiscal Period: December |
2022 Q2
|
2022 S1
|
2022 S2
|
2023 S1
|
2023 S2
|
2024 S1
|
2024 S2
|
---|
Net sales
1 |
-
|
-
|
-
|
19.06
|
-
|
-
|
-
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net income
|
-
|
-
|
-
|
-
|
-223
|
-306.4
|
-390
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
|
-
|
-
|
-
|
-
|
-0.3500
|
-0.3700
|
-0.4500
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
8/22/22
|
8/22/22
|
3/15/23
|
8/15/23
|
3/12/24
|
-
|
-
|
Fiscal Period: December |
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
2,492
|
2,213
|
1,971
|
1,928
|
1,385
|
702
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-179
|
-364
|
-454
|
-176
|
-12
|
-323
|
ROE (net income / shareholders' equity)
|
-253%
|
-20.3%
|
-19.9%
|
-1.9%
|
-34.7%
|
-62.7%
|
ROA (Net income/ Total Assets)
|
-109%
|
-20.6%
|
-19.4%
|
-2.3%
|
-
|
-
|
Assets
1 |
1,660
|
2,402
|
2,225
|
22,499
|
-
|
-
|
Book Value Per Share
2 |
3.610
|
3.780
|
3.060
|
2.770
|
1.760
|
0.9200
|
Cash Flow per Share
2 |
-0.7200
|
-0.5500
|
-0.6900
|
-0.2400
|
-
|
-
|
Capex
1 |
9.01
|
19.6
|
12.3
|
25
|
25
|
25
|
Capex / Sales
|
39.74%
|
-
|
64.28%
|
14.88%
|
9.81%
|
8.03%
|
Announcement Date
|
3/18/22
|
3/15/23
|
3/12/24
|
-
|
-
|
-
|
Last Close Price
3.097
CNY Average target price
7.572
CNY Spread / Average Target +144.44% Consensus |
1st Jan change
|
Capi.
|
---|
| -8.49% | 277M | | +10.79% | 116B | | +11.65% | 106B | | -6.20% | 23.89B | | -3.29% | 21.58B | | -11.39% | 18.96B | | -13.41% | 16.33B | | -40.50% | 16.96B | | +6.64% | 14.14B | | +31.84% | 12.02B |
Bio Therapeutic Drugs
|